Search research articles
Contact Us
Filters
Showing results (1-10 of 165) with videos related to
Page
of 17
Sort By:
Arerugi = [Allergy]
|
June 16, 2024
[HUMAN LEUKOCYTE ANTIGEN (HLA) GENES ASSOCIATED WITH DRUG ERUPTIONS AND OTHER DRUG ALLERGIC SIDE EFFECTS]
Taisei Mushiroda
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
|
March 3, 2024
[Pharmacogenetic testing for prevention of severe cutaneous adverse drug reactions]
Taisei Mushiroda
Rinsho Byori. the Japanese Journal of Clinical Pathology
|
April 15, 2014
[Future direction of pharmacogenomics: identification of genes associated with risk of adverse drug reactions using genome-wide association study]
Taisei Mushiroda
Allergology International : Official Journal of the Japanese Society of Allergology
|
April 5, 2025
Pharmacogenetic biomarkers associated with risk of developing severe drug eruptions and clinical implementation of HLA genetic testing
Taisei Mushiroda
Rinsho Byori. the Japanese Journal of Clinical Pathology
|
August 17, 2013
[Challenge in genome-wide association study for establishment of personalized medicine: focusing on the pharmacogenomics of warfarin and carbamazepine]
Taisei Mushiroda
Journal of Human Genetics
|
May 9, 2022
Avoidance of cutaneous adverse drug reactions induced by antiepileptic drugs based on pharmacogenomics
Taisei Mushiroda
Genome Medicine
|
June 4, 2011
Personalizing carbamazepine therapy
Taisei Mushiroda, Yusuke Nakamura
The Lancet. Psychiatry
|
March 6, 2018
The genetics of antipsychotic response in schizophrenia
Masashi Ikeda, Taisei Mushiroda
Drug Metabolism and Pharmacokinetics
|
January 28, 2021
Update on next generation sequencing of pharmacokinetics-related genes: Development of the PKseq panel, a platform for amplicon sequencing of drug-metabolizing enzyme and drug transporter genes
Koya Fukunaga, Yukihide Momozawa, Taisei Mushiroda
Drug Metabolism and Pharmacokinetics
|
October 27, 2018
Gap between the US and Japan in coverage of pharmacogenomic biomarkers by health insurance programs: More coverage is needed in Japan
Keiko Hikino, Koya Fukunaga, Taisei Mushiroda
Page
of 17
Search research articles
Search
Showing results (1-10 of 165) with videos related to
Sort By:
Page
of 17
Arerugi = [Allergy]
|
June 16, 2024
[HUMAN LEUKOCYTE ANTIGEN (HLA) GENES ASSOCIATED WITH DRUG ERUPTIONS AND OTHER DRUG ALLERGIC SIDE EFFECTS]
Taisei Mushiroda
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
|
March 3, 2024
[Pharmacogenetic testing for prevention of severe cutaneous adverse drug reactions]
Taisei Mushiroda
Rinsho Byori. the Japanese Journal of Clinical Pathology
|
April 15, 2014
[Future direction of pharmacogenomics: identification of genes associated with risk of adverse drug reactions using genome-wide association study]
Taisei Mushiroda
Allergology International : Official Journal of the Japanese Society of Allergology
|
April 5, 2025
Pharmacogenetic biomarkers associated with risk of developing severe drug eruptions and clinical implementation of HLA genetic testing
Taisei Mushiroda
Rinsho Byori. the Japanese Journal of Clinical Pathology
|
August 17, 2013
[Challenge in genome-wide association study for establishment of personalized medicine: focusing on the pharmacogenomics of warfarin and carbamazepine]
Taisei Mushiroda
Journal of Human Genetics
|
May 9, 2022
Avoidance of cutaneous adverse drug reactions induced by antiepileptic drugs based on pharmacogenomics
Taisei Mushiroda
Genome Medicine
|
June 4, 2011
Personalizing carbamazepine therapy
Taisei Mushiroda, Yusuke Nakamura
The Lancet. Psychiatry
|
March 6, 2018
The genetics of antipsychotic response in schizophrenia
Masashi Ikeda, Taisei Mushiroda
Drug Metabolism and Pharmacokinetics
|
January 28, 2021
Update on next generation sequencing of pharmacokinetics-related genes: Development of the PKseq panel, a platform for amplicon sequencing of drug-metabolizing enzyme and drug transporter genes
Koya Fukunaga, Yukihide Momozawa, Taisei Mushiroda
Drug Metabolism and Pharmacokinetics
|
October 27, 2018
Gap between the US and Japan in coverage of pharmacogenomic biomarkers by health insurance programs: More coverage is needed in Japan
Keiko Hikino, Koya Fukunaga, Taisei Mushiroda
Page
of 17